Hunter Perkins Capital Management LLC Acquires Shares of 8,482 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hunter Perkins Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 8,482 shares of the biopharmaceutical company’s stock, valued at approximately $5,380,000. Regeneron Pharmaceuticals makes up 1.2% of Hunter Perkins Capital Management LLC’s holdings, making the stock its 26th biggest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Illinois Municipal Retirement Fund grew its stake in shares of Regeneron Pharmaceuticals by 14.6% in the 1st quarter. Illinois Municipal Retirement Fund now owns 21,837 shares of the biopharmaceutical company’s stock valued at $13,850,000 after buying an additional 2,774 shares during the period. Diversified Trust Co lifted its holdings in Regeneron Pharmaceuticals by 23.3% in the first quarter. Diversified Trust Co now owns 2,874 shares of the biopharmaceutical company’s stock valued at $1,823,000 after acquiring an additional 544 shares during the last quarter. PDS Planning Inc increased its stake in Regeneron Pharmaceuticals by 24.6% during the first quarter. PDS Planning Inc now owns 421 shares of the biopharmaceutical company’s stock worth $267,000 after acquiring an additional 83 shares during the last quarter. Creative Financial Designs Inc. ADV raised its position in Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 19 shares during the period. Finally, Golden State Wealth Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 265.4% during the 1st quarter. Golden State Wealth Management LLC now owns 95 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 69 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Guggenheim restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a report on Monday, June 9th. Citigroup cut their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating on the stock in a report on Monday, June 2nd. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research note on Monday, June 2nd. Finally, Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $822.58.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $521.00 on Friday. The business’s 50-day moving average price is $555.02 and its 200 day moving average price is $634.70. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a market capitalization of $56.25 billion, a PE ratio of 13.26, a price-to-earnings-growth ratio of 1.91 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. During the same quarter in the previous year, the company earned $9.55 earnings per share. The company’s revenue was down 3.7% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.